Human PAI-1 (wild type active fraction)

$695$1,140

Clear
SKU: PAI-A Categories: ,

Product Description

Human wild type PAI-1 is produced as an active and latent form in E. Coli. The purification conditions are gentle and result in an active fraction >99percent pure and >98percent active as determined by titration with HMW tc-urokinase and SDS PAGE.

Gene ID: 5054
Swiss-Prot/UniProt ID: P05121

View sample datasheet
View sample certificate of analysis
View material safety data sheet
Ask a question about this product

Additional Information

Purity

Source

Molecular Weight

Extinction Coefficient

Species

Storage

Shipping Conditions

Expiration

Form

Buffer

Sample Size

Sample Concentration

Sample Volume

Gene Name

Gene ID

UniProt ID

1. Iafrati MD, Vitseva O, Tanriverdi K et-al. Compensatory mechanisms influence hemostasis in setting of eNOS deficiency. Am. J. Physiol. Heart Circ. Physiol. 2005;288 (4): H1627-32. doi:10.1152/ajpheart.00819.2004Pubmed citation

2. Jo M, Thomas KS, Marozkina N et-al. Dynamic assembly of the urokinase-type plasminogen activator signaling receptor complex determines the mitogenic activity of urokinase-type plasminogen activator. J. Biol. Chem. 2005;280 (17): 17449-57. doi:10.1074/jbc.M413141200Pubmed citation

3. Chai J, Charboneau AL, Betz BL et-al. Loss of the hSNF5 gene concomitantly inactivates p21CIP/WAF1 and p16INK4a activity associated with replicative senescence in A204 rhabdoid tumor cells. Cancer Res. 2005;65 (22): 10192-8. doi:10.1158/0008-5472.CAN-05-1896Pubmed citation

4. Chu JW, Abbasi F, Lamendola C et-al. Effect of rosiglitazone treatment on circulating vascular and inflammatory markers in insulin-resistant subjects. Diab Vasc Dis Res. 2005;2 (1): 37-41. doi:10.3132/dvdr.2005.004Pubmed citation

5. Moran P, Li W, Fan B et-al. Pro-urokinase-type plasminogen activator is a substrate for hepsin. J. Biol. Chem. 2006;281 (41): 30439-46. doi:10.1074/jbc.M605440200Pubmed citation

6. O’connor JC, Farach-carson MC, Schneider CJ et-al. Coculture with prostate cancer cells alters endoglin expression and attenuates transforming growth factor-beta signaling in reactive bone marrow stromal cells. Mol. Cancer Res. 2007;5 (6): 585-603. doi:10.1158/1541-7786.MCR-06-0408Pubmed citation

7. Inagi R, Izuhara Y, Tominaga N et-al. Establishment of a sandwich ELISA for human megsin, a kidney-specific serine protease inhibitor. Nephrol. Dial. Transplant. 2007;22 (11): 3311-7. doi:10.1093/ndt/gfm391Pubmed citation

8. Norris EH, Strickland S. Modulation of NR2B-regulated contextual fear in the hippocampus by the tissue plasminogen activator system. Proc. Natl. Acad. Sci. U.S.A. 2007;104 (33): 13473-8. doi:10.1073/pnas.0705848104Free text at pubmedPubmed citation

9. Schar CR, Blouse GE, Minor KH et-al. A deletion mutant of vitronectin lacking the somatomedin B domain exhibits residual plasminogen activator inhibitor-1-binding activity. J. Biol. Chem. 2008;283 (16): 10297-309. doi:10.1074/jbc.M708017200Free text at pubmedPubmed citation

10. Li SH, Gorlatova NV, Lawrence DA et-al. Structural differences between active forms of plasminogen activator inhibitor type 1 revealed by conformationally sensitive ligands. J. Biol. Chem. 2008;283 (26): 18147-57. doi:10.1074/jbc.M709455200Free text at pubmedPubmed citation

11. Vial D, Mckeown-longo PJ. PAI1 stimulates assembly of the fibronectin matrix in osteosarcoma cells through crosstalk between the alphavbeta5 and alpha5beta1 integrins. J. Cell. Sci. 2008;121 (Pt 10): 1661-70. doi:10.1242/jcs.020149Free text at pubmedPubmed citation

12. Chen SC, Henry DO, Reczek PR et-al. Plasminogen activator inhibitor-1 inhibits prostate tumor growth through endothelial apoptosis. Mol. Cancer Ther. 2008;7 (5): 1227-36. doi:10.1158/1535-7163.MCT-08-0051Pubmed citation

13. Lund IK, Jögi A, Rønø B et-al. Antibody-mediated targeting of the urokinase-type plasminogen activator proteolytic function neutralizes fibrinolysis in vivo. J. Biol. Chem. 2008;283 (47): 32506-15. doi:10.1074/jbc.M801924200Pubmed citation

14. Adair JE, Stober V, Sobhany M et-al. Inter-alpha-trypsin inhibitor promotes bronchial epithelial repair after injury through vitronectin binding. J. Biol. Chem. 2009;284 (25): 16922-30. doi:10.1074/jbc.M808560200Free text at pubmedPubmed citation

15. Fjellström O, Deinum J, Sjögren T et-al. Characterization of a small molecule inhibitor of plasminogen activator inhibitor type 1 that accelerates the transition into the latent conformation. J. Biol. Chem. 2013;288 (2): 873-85. doi:10.1074/jbc.M112.371732Free text at pubmedPubmed citation

16. Florova G, Karandashova S, Declerck PJ et-al. Remarkable stabilization of plasminogen activator inhibitor 1 in a “molecular sandwich” complex. Biochemistry. 2013;52 (27): 4697-709. doi:10.1021/bi400470sFree text at pubmedPubmed citation

17. Boe AE, Eren M, Murphy SB et-al. Plasminogen activator inhibitor-1 antagonist TM5441 attenuates Nω-nitro-L-arginine methyl ester-induced hypertension and vascular senescence. Circulation. 2013;128 (21): 2318-24. doi:10.1161/CIRCULATIONAHA.113.003192Free text at pubmedPubmed citation

18. Komissarov AA, Florova G, Azghani A et-al. Active α-macroglobulin is a reservoir for urokinase after fibrinolytic therapy in rabbits with tetracycline-induced pleural injury and in human pleural fluids. Am. J. Physiol. Lung Cell Mol. Physiol. 2013;305 (10): L682-92. doi:10.1152/ajplung.00102.2013Free text at pubmedPubmed citation

19. Damare J, Brandal S, Fortenberry YM. Inhibition of PAI-1 antiproteolytic activity against tPA by RNA aptamers. Nucleic Acid Ther. 2014;24(4):239-49. Link to article

20. Komissarov AA, Florova G, Azghani AO, et al. The time course of resolution of adhesions during fibrinolyitic therapy in tetracycline-induced pleural injury in rabbits. Am J Physiol Lung Cell Mol Physiol. 2015;:ajplung.00136.2015. link to article

21. Florova G, Azghani AO, Karandashova S, et al. Targeting Plasminogen Activator Inhibitor 1 in Tetracycline-Induced Pleural Injury in Rabbits. Am J Physiol Lung Cell Mol Physiol. 2017;:ajplung.00579.2016. Link to article

You may also like…